Dr. Somlo on Novel Agents in Multiple Myeloma

George Somlo, MD
Published: Monday, Oct 17, 2016



George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.

Several new agents have been approved by the FDA in the past year, and oncologists are currently learning how to best utilize them, especially in combination with one another, explains Somlo.

The overall goal, says Somlo, is to both improve the toxicity profile of some of the older agents in this space, as well as bring the novel agents into the frontline setting.


George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.

Several new agents have been approved by the FDA in the past year, and oncologists are currently learning how to best utilize them, especially in combination with one another, explains Somlo.

The overall goal, says Somlo, is to both improve the toxicity profile of some of the older agents in this space, as well as bring the novel agents into the frontline setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x